Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia

Open access
Ottaviano, Giorgio, Georgiadis, Christos, Gkazi, Soragia Athina, Syed, Farhatullah, Zhan, Hong, Etuk, Annie, Preece, Roland, Chu, Jan, Kubat, Agnieszka, Adams, Stuart, Veys, Paul, Vora, Ajay, Rao, Kanchan, Qasim, Waseem, for the TT52 CRISPR-CAR group, James, Jesmina, Gilmour, Kimberly, Inglott, Sarah, Thomas, Rebecca, Mhaldien, Lana, Hasnain, Attia, Izotova, Natalia, Tailor, Nina, Flutter, Barry, Ahmed, Batoul, Braybrook, Toni, Pinner, Danielle, Williams, Lindsey, Ko, Ka-Yuk, Taylor, Anna, Eshilokun, Adebimpe, Staddon, Susan, Amrolia, Persis, Chiesa, Robert, Lucchini, Giovanna, Lazareva, Arina, Mullanfiroze, Khushnuma, Hill, Annette, Finch, Maria, Mead, Rachel, Young, Lindsey, Abbott, Christopher, Ancliff, Philip, Ghorashian, Sara, Samarasinghe, Sujith, Rao, Anupama, Bartram, Jack, Pavasovic, Vesna, Cheng, Danny, Eddaoudi, Ayad, Farzaneh, Farzin, Domning, Sabine, Heimke, Rene, Gabriel, Richard, Sauer, Martin, Beier, Rita, Madeleine, Kirste, Eckert, Cornelia, Schilham, Marco Willem, Jansen-Hoogendijk, Anja Magdalena, Kim, Jin Soo, Kim, Daesik · 2022 · Science Translational Medicine

Abstract

Genome editing of allogeneic T cells can provide “off-the-shelf” alternatives to autologous chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain (TRAC) to prevent graft-versus-host disease (GVHD) and removal of CD52 (cluster of differentiation 52) for a survival advantage in the presence of alemtuzumab have previously been investigated using transcription activator–like effector nuclease (TALEN)-mediated knockout. Here, we deployed next-generation CRISPR-Cas9 editing and linked CAR expression to multiplexed DNA editing of TRAC and CD52 through incorporation of self-duplicating CRISPR guide RNA expression cassettes within the 3’ long terminal repeat of a CAR19 lentiviral vector. Three cell banks of TT52CAR19 T cells were generated and cryopreserved. A phase 1, open-label, non-randomized clinical trial was conducted and treated six children with relapsed/refractory CD19-positive B cell acute lymphoblastic leukemia (B-ALL) (NCT04557436). Lymphodepletion included fludarabine, cyclophosphamide, and alemtuzumab and was followed by a single infusion of 0.8 × 10 6 to 2.0 × 10 6 CAR19 T cells per kilogram with no immediate toxicities. Four of six patients infused with TT52CAR19 T cells exhibited cell expansion, achieved flow cytometric remission, and then proceeded to receive allogeneic stem cell transplantation. Two patients required biological intervention for grade II cytokine release syndrome, one patient developed transient grade IV neurotoxicity, and one patient developed skin GVHD, which resolved after transplant conditioning. Other complications were within expectations, and primary safety objectives were met. This study provides a demonstration of the feasibility, safety, and therapeutic potential of CRISPR-engineered immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abq3010

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 199

Metadata

Authors
Ottaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., Preece, R., Chu, J., Kubat, A., Adams, S., Veys, P., Vora, A., Rao, K., Qasim, W., for the TT52 CRISPR-CAR group, James, J., Gilmour, K., Inglott, S., Thomas, R., Mhaldien, L., Hasnain, A., Izotova, N., Tailor, N., Flutter, B., Ahmed, B., Braybrook, T., Pinner, D., Williams, L., Ko, K.-Y., Taylor, A., Eshilokun, A., Staddon, S., Amrolia, P., Chiesa, R., Lucchini, G., Lazareva, A., Mullanfiroze, K., Hill, A., Finch, M., Mead, R., Young, L., Abbott, C., Ancliff, P., Ghorashian, S., Samarasinghe, S., Rao, A., Bartram, J., Pavasovic, V., Cheng, D., Eddaoudi, A., Farzaneh, F., Domning, S., Heimke, R., Gabriel, R., Sauer, M., Beier, R., Madeleine, K., Eckert, C., Schilham, M. W., Jansen-Hoogendijk, A. M., Kim, J. S., & Kim, D.
Venue
Science Translational Medicine
Published
2022-10-26
Volume
14
Issue
668
Pages
eabq3010-eabq3010
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W4307309183
Cited by
199
References
15
FWCI
13.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. https://app.cochat.ai/papers/10.1126/scitranslmed.abq3010
The paper
Ottaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., Preece, R., Chu, J., Kubat, A., Adams, S., Veys, P., Vora, A., Rao, K., Qasim, W., for the TT52 CRISPR-CAR group, James, J., Gilmour, K., Inglott, S., Thomas, R., . . . Kim, D. (2022). Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abq3010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.